VAXNEUVANCE 2 ug/.5mL

VAXNEUVANCE 2 ug/0.5mL is a pneumococcal 15-valent conjugate vaccine designed for intramuscular administration. This vaccine helps protect against pneumococcal diseases caused by 15 serotypes. Ideal for those seeking immunization, it is manufactured by Merck Sharp & Dohme LLC in the USA.

VAXNEUVANCE 2 ug/0.5mL is used to prevent pneumococcal diseases, including infections caused by 15 different serotypes of the Streptococcus pneumoniae bacteria. This vaccine is typically administered to individuals who are at risk of pneumococcal infections, such as young children and adults with certain medical conditions. It is often recommended as part of a routine immunization schedule to help reduce the risk of serious illnesses like pneumonia, meningitis, and bacteremia.

Common effects of VAXNEUVANCE 2 ug/0.5mL may include mild to moderate reactions at the injection site, such as redness, swelling, and pain. Some individuals may also experience general symptoms like fever, fatigue, and muscle aches. These effects are usually temporary and resolve on their own within a few days. Severe reactions are rare but should be reported to a healthcare provider immediately.

VAXNEUVANCE 2 ug/0.5mL should be administered by a healthcare professional. It is important to inform your healthcare provider about any allergies, particularly to any components of the vaccine, or if you have a history of severe allergic reactions to previous vaccinations. Individuals with weakened immune systems or those taking immunosuppressive medications should consult their healthcare provider before receiving this vaccine.

VAXNEUVANCE 2 ug/0.5mL may interact with certain medications, particularly those that affect the immune system. It is important to discuss all current medications with your healthcare provider before receiving this vaccine. Additionally, avoid taking over-the-counter pain relievers or fever reducers around the time of vaccination unless directed by a healthcare provider, as they may interfere with the vaccine's effectiveness.